The event: Phase IIb study of SB-509 in diabetic neuropathy.
The timeline: Top-line results to be announced in the second half of 2011.
The stakes: The legitimacy of zinc-finger drug technology, which Sangamo has been developing for years on its own. SB-509 is an engineered protein, or "zinc finger," specifically designed to turn on a gene to restart nerve growth. Previously reported data from earlier studies of SB-509 in diabetic neuropathy have produced mixed results and a significant level of investor skepticism about the technology.